[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=888e4ec04b1310242c14f5d64377881481965594ea39e0c8ec990bd6768f012b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747240560,
      "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134470853,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=888e4ec04b1310242c14f5d64377881481965594ea39e0c8ec990bd6768f012b"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "BBH: Fear Of Price Controls Is Not The Problem",
    "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
    "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747213200,
      "headline": "BBH: Fear Of Price Controls Is Not The Problem",
      "id": 134435713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200850893/image_2200850893.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
      "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Equity Fund Q1 2025 Commentary",
    "summary": "Parnassus Value Equity Fund (Investor Shares) returned -1.98% (net of fees) for the quarter, underperforming the Russell 1000 Value Indexâs 2.14%.",
    "url": "https://finnhub.io/api/news?id=28be985f5e53631e0225d2794d521c1d6c9324a5c17f9539f9dc07555c958fc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747210140,
      "headline": "Parnassus Value Equity Fund Q1 2025 Commentary",
      "id": 134435282,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363842522/image_1363842522.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Parnassus Value Equity Fund (Investor Shares) returned -1.98% (net of fees) for the quarter, underperforming the Russell 1000 Value Indexâs 2.14%.",
      "url": "https://finnhub.io/api/news?id=28be985f5e53631e0225d2794d521c1d6c9324a5c17f9539f9dc07555c958fc9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Overvalued Now (Rating Downgrade)",
    "summary": "Gilead Sciences struggles to diversify beyond viral treatments despite market outperformance.",
    "url": "https://finnhub.io/api/news?id=dd809d51f8724ddbab43d8d67ec62375aface93906344f6e267593d0bf3c7fd9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747208285,
      "headline": "Gilead Sciences Is Overvalued Now (Rating Downgrade)",
      "id": 134435050,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences struggles to diversify beyond viral treatments despite market outperformance.",
      "url": "https://finnhub.io/api/news?id=dd809d51f8724ddbab43d8d67ec62375aface93906344f6e267593d0bf3c7fd9"
    }
  }
]